New Market Study Published: Product Profiles: Non-Small Cell Lung Cancer
The non-small cell lung cancer pipeline is growing as a result of an increased understanding of the disease's heterogeneity, which has led to the development of personalized therapies targeting distinct patient subtypes. The success of these personalized therapies is likely to incentivize pharmaceutical companies to continue developing targeted therapies for niche patient populations.
View full press release